Glofitamab-gxbm

(Columvi)

Glofitamab-gxbm

Drug updated on 11/27/2023

Dosage FormInjection (intravenous, 2.5 mg/2.5 mL (1 mg/mL) in a single-dose vial, 10 mg/10 mL (1 mg/mL) in a single-dose vial)
Drug ClassCD20-directed CD3 T-cell engagers
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, who have had two or more lines of systemic therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Columvi (glofitamab-gxbm) Prescribing Information.2023Genentech Inc., South San Francisco, CA

Randomized Controlled Trials


Sex Distribution:

F:35%
M:65%
154Subjects

Year:

2022

Source:The New England Journal of Medicine